mirtazapine / Generic mfg. - LARVOL DELTA

Development and optimization of mirtazapine loaded lipid-based transethosomal gel; in-vitro, ex-vivo and toxicological analysis. (PubMed, Pak J Pharm Sci) - "These findings and the study suggests that the transethosomal gel formulation is a promising and safe approach for transdermal delivery of mirtazapine, potentially improving its bioavailability and therapeutic effectiveness resulting in bypassing first pass metabolism."

Journal • Preclinical • Inflammation

Charles bonnet syndrome with subsequent depression in acute angle-closure glaucoma: a case report. (PubMed, Oxf Med Case Reports) - "CBS was diagnosed, and hallucinations resolved with reassurance and low-dose clonazepam. Several weeks later, the patient developed moderate depression (HAM-D = 18), successfully treated with mirtazapine. At three months, he remained asymptomatic. This case is unusual for its association of CBS with angle-closure glaucoma and subsequent depression, underscoring the need for proactive inquiry, de-stigmatization, and integrated ophthalmic-psychiatric care."

Journal • Age-related Macular Degeneration • CNS Disorders • Depression • Glaucoma • Macular Degeneration • Mood Disorders • Ophthalmology • Psychiatry • Retinal Disorders

Efficacy of Clotiazepam for Respiratory Dyskinesia in a Patient With Parkinsonism: A Case Report. (PubMed, Cureus) - "These symptoms became prominent following the upward titration of a ropinirole patch to 24 mg/day. Although mirtazapine was subsequently added to address comorbid depressive symptoms, it failed to alleviate his respiratory distress...Our findings suggest that the anxiolytic and GABA-mediated muscle-relaxant properties of clotiazepam, combined with its favorable safety profile for the elderly due to its short half-life, may provide a useful and effective new therapeutic option for the management of refractory respiratory dyskinesia. Although the limitations of drawing conclusions from a single case must be acknowledged, these results warrant further large-scale prospective studies to validate the efficacy and safety of clotiazepam in this population."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease • Pulmonary Disease

Treatment of glomerular and tubular proteinuria in the nephrotic range in a female cat: case report. (PubMed, Braz J Vet Med) - "Treatment included furosemide, dexamethasone, benazepril, omega-3 fatty acid, mirtazapine and renal diet, in addition to procedures such as paracentesis for drainage. The patient remained stable, with no recurrence of symptoms. The therapeutic conclusions are limited by the single-case design, although continuous clinical and laboratory monitoring was implemented, aiming to adjust therapeutic management."

Journal • Glomerulonephritis • Nephrology • Pulmonary Disease • Renal Disease

Box-Behnken optimized green analytical method for mirtazapine detection using N,P CQDs with quantum mechanical mechanistic elucidation and sustainability assessment. (PubMed, Spectrochim Acta A Mol Biomol Spectrosc) - "Finally, green chemistry assessment using AGREE (0.72), BAGI (77.5), and RGB12 (89.0% whiteness) tools confirmed superior sustainability compared to conventional methods. The developed method offers a cost-effective, environmentally friendly alternative for routine mirtazapine analysis in pharmaceutical quality control and environmental monitoring, addressing the growing need for sustainable analytical approaches while maintaining excellent analytical performance."

Journal

Idiopathic Pruritus in People Living with HIV: A Narrative Review (AAD 2026) - "Symptomatic treatments include antihistamines, gabapentinoids, mirtazapine, and emollients... Idiopathic pruritus in PLWHA is prevalent and multifactorial but lacks high-quality evidence to guide care. Future priorities include multicenter prevalence studies, validated diagnostic criteria, randomized controlled trials of targeted therapies, and integration of psychodermatology into HIV care."

Review • CNS Disorders • Depression • Dermatology • Human Immunodeficiency Virus • Infectious Disease • Mood Disorders • Pruritus • Sleep Disorder • CD4 • IL13 • IL4

Psychotropic drug-induced obesity in older adults: complications, preventive and therapeutic interventions (PubMed, Orv Hetil) - "Among psychotropic drugs, olanzapine, clozapine, quetiapine, mirtazapine, valproate, and lithium are associated with the most significant weight gain through complex mechanisms (H1 blockade, 5-HT2C antagonism, metabolic effects); however, other antipsychotics, mood stabilizers, and antidepressants may also contribute to weight increase...Prevention hinges on preferring agents with lower metabolic risk (e.g., aripiprazole, venlafaxine, lamotrigine), regular monitoring, and proactive lifestyle interventions. Therapeutically, switching medications, intensive lifestyle programs, metformin, or GLP1 agonists may be employed...Orv Hetil. 2026; 167(11): 410-418."

Journal • Review • Cardiovascular • CNS Disorders • Diabetes • Genetic Disorders • Geriatric Disorders • Metabolic Disorders • Obesity • Oncology • Sarcopenia

Antidepressants and bleeding risk: Expert consensus from the Association of Medicine and Psychiatry. (PubMed, J Psychosom Res) - "The proposed algorithm can aid clinicians in determining whether antidepressant (including SRI) initiation, discontinuation, or dose adjustment should be considered for patients susceptible to bleeding. These guidelines preserve a role for clinical judgment in selection of treatments that balance the risks and benefits, which may be particularly relevant for patients with complex medical and psychiatric comorbidities. Additional studies are needed to better guide clinical decision making."

Journal • Cerebral Hemorrhage • CNS Disorders • Gastroenterology • Hematological Disorders • Psychiatry

Clinical Potential of Mirtazapine in Anxiety and Trauma-Related Disorders: A Systematic Review and Meta-Analysis of Current Evidence. (PubMed, Hum Psychopharmacol) - "Mirtazapine was more effective than SSRIs for anxiety in MDD and may be preferred when anxiety is relevant. In GAD, mirtazapine may serve as an alternative to first-line agents, and further regulatory explorations are warranted. In PTSD, mirtazapine has potential as an augmentation strategy. Mirtazapine was generally well tolerated and may be advantageous for patients requiring rapid effect or relief from sleep disturbances."

Clinical • Journal • Retrospective data • Review • CNS Disorders • Depression • General Anxiety Disorder • Major Depressive Disorder • Mood Disorders • Post-traumatic Stress Disorder • Psychiatry • Sleep Disorder

Association between concomitant use of direct oral anticoagulants with antidepressants and an increased risk of hemorrhage: analysis of the food and drug administration adverse event reporting system database. (PubMed, Front Med (Lausanne)) - "Selective serotonin reuptake inhibitors (SSRIs) presented the highest class risk (ROR 1.78, 95% CI 1.54-2.04), with apixaban plus paroxetine showing the strongest signal (ROR 14.12, 95% CI 7.62-26.15). Co-administration of antidepressants and DOACs significantly elevates bleeding risk, especially for the nervous system. Clinicians must exercise heightened caution, particularly with SSRIs and when using mirtazapine, and further validation studies are needed."

Adverse events • Journal • Hematological Disorders • ROR1

Mirtazapine for the treatment of irritable bowel syndrome: A systematic review. (PubMed, World J Methodol) - "Although evidence is limited, current data indicate Mirtazapine improves IBS-related symptoms and associated mental health issues, with rapid onset and good tolerability. The small number of studies and absence of large-scale RCTs warrant cautious interpretation. Further RCTs are essential to confirm Mirtazapine's role in IBS treatment and define optimal patient profiles."

Journal • CNS Disorders • Constipation • Depression • Gastroenterology • Gastrointestinal Disorder • Inflammatory Bowel Disease • Insomnia • Mood Disorders • Pain • Psychiatry • Sleep Disorder

Central and Peripheral Neuromodulators in Functional Dyspepsia and Gastroparesis: A Symptom-Based Clinical Review. (PubMed, Neurogastroenterol Motil) - "Neuromodulators provide a rational, mechanism-based treatment option for FD and GP, and a symptom-oriented approach may optimize patient outcomes; although high-quality, subtype-specific trials are needed to strengthen the evidence base."

Journal • Review • Cardiovascular • CNS Disorders • Dyspepsia • Gastrointestinal Disorder • Immunology • Infectious Disease • Musculoskeletal Pain • Pain • Psychiatry

The Usefulness of Neuromodulators in Clinical Practice: The Gastroenterologist's Viewpoint (PubMed, Acta Gastroenterol Latinoam) - "Other drugs, such as gabapentinoids, mirtazapine, buspirone, and certain antipsychotics, have also shown benefits in specific phenotypes...In addition, a multidisciplinary approach integrating non-pharmacological interventions such as cognitive-behavioral therapy, gut-directed hypnotherapy, and mindfulness-based programs, is recommended. This combination enhances clinical effectiveness, reduces stigma, and improves quality of life, consolidating neuromodulators as an essential part of the comprehensive treatment of disorders of brain-gut interaction."

Journal • Review • CNS Disorders • Depression • Gastrointestinal Disorder • Immunology • Mental Retardation • Mood Disorders • Pain • Psychiatry

Long-term safety evaluation of mirtazapine: A real-world pharmacovigilance study based on the FAERS database. (PubMed, PLoS One) - "This study systematically assessed the long-term safety profile of mirtazapine using 21 years of real-world pharmacovigilance data from the FAERS database. The findings provide important evidence to support safe clinical use of mirtazapine and emphasize the need for continuous safety monitoring."

Adverse events • Journal • Real-world evidence • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Movement Disorders • Psychiatry • Restless Legs Syndrome • Sleep Disorder • Suicidal Ideation

TOP 5 QT-PROLONGING DRUG-DRUG INTERACTIONS (QT-DDIS) IN ELDERLY PSYCHIATRY INPATIENTS RECEIVING PSYCHOTROPICS: A CROSS-SECTIONAL EVALUATION FROM NORTHEAST INDIA (ISPOR 2026) - "The top five QT-DDIs were escitalopram-quetiapine (n=3), escitalopram-olanzapine (n=2), escitalopram-paroxetine (n=2), escitalopram-donepezil (n=2), and escitalopram-mirtazapine (n=2). QT-prolonging DDIs are common among elderly psychiatric inpatients and represent a preventable source of adverse cardiac events and cost escalation. Incorporation of clinical decision support systems (CDSS) such as MedSafety Scan (MSS) hosted by AZCERT's CredibleMeds utilizing AZCERT and DDI databases can optimize prescribing, reduce iatrogenic risk, and improve cost-effectiveness in psychotropic management for the elderly. Such reliable clinical support tools, can provide comprehensive analyses of TdP risk, drug interactions, and duplicate therapies, and produce a detailed patient-specific report that allows for documentation of management plans and pharmacotherapeutic adjustments."

Clinical • CNS Disorders • Psychiatry

Successful Treatment of Refractory Gastroparesis-related Nausea in Parkinson's Disease with Mirtazapine (AAN 2026) - "Proton pump inhibitors and ondansetron were ineffective. Importantly, nausea occurred independently of levodopa dose timing and did not improve with typical management including additional carbidopa, reduction of dopaminergic medications, or administration with food, suggesting symptoms were unrelated to dopaminergic therapy...Trials of CBD/THC, scopolamine, and vagal nerve stimulation (GammaCore) provided limited benefit... Mirtazapine may offer a valuable off-label option for treating refractory nausea related to gastroparesis in PD. Its multimodal serotonergic and noradrenergic effects may enhance gastric motility and antiemetic response where standard agents fail."

CNS Disorders • Constipation • Gastroenterology • Gastrointestinal Disorder • Movement Disorders • Parkinson's Disease • Sleep Disorder

Naltrexone/Bupropion/Mirtazapine Triple Therapy for Treatment-Resistant Methamphetamine Use Disorder: A Case Series. (PubMed, Cureus) - "Here, we present a case series of three patients with severe, treatment-resistant methamphetamine use disorder treated with a combination of NTX/BUP/MIRT for 18-24 months. The complementary pharmacologic profiles of the three agents may produce synergistic benefits by targeting craving, withdrawal, mood instability, and insomnia. While encouraging, these findings require validation in controlled clinical trials."

Clinical • Journal • CNS Disorders • Insomnia • Psychiatry • Sleep Disorder

Safety of Intravenous Methamphetamine in Patients Taking Mirtazapine: A Two-Site Phase 1b Randomized Controlled Trial. (PubMed, J Clin Psychopharmacol) - "Mirtazapine 30 mg was safe and well-tolerated in people receiving a clinically relevant intravenous methamphetamine challenge, supporting further development of this medication for the treatment of methamphetamine use disorder."

Clinical • Journal • P1 data • Cardiovascular • CNS Disorders

Persistence of antidepressant treatment in children and adolescents: A population-based cohort study. (PubMed, Aust N Z J Psychiatry) - "Persistent antidepressant use beyond 1 or 2 years is common among children and adolescents and shows an increasing trend over time. The reasons for and appropriateness of prolonged treatment with antidepressants in this population warrant further investigation."

Journal • CNS Disorders • Depression • Psychiatry

Beyond the Gut: A Case Report of Antibiotic-Induced Dysbiosis as a Hidden Cause of Chronic Insomnia. (PubMed, Cureus) - "Several months later, he developed severe insomnia, unresponsive to melatonin, mirtazapine, CBT-I, and multiple hypnotics, including zolpidem and lemborexant. Clinicians should consider gut microbiome assessment in persistent insomnia, particularly in patients with extensive antibiotic exposure. Further research is warranted to elucidate mechanisms and validate microbiome-targeted therapies."

Journal • Acute Lymphocytic Leukemia • CNS Disorders • Hematological Malignancies • Insomnia • Leukemia • Oncology • Sleep Disorder • Transplantation

Management of insomnia symptoms in depressed patients treated with agomelatine, mirtazapine and trazodone: A systematic review and meta-analysis. (PubMed, J Affect Disord) - "All three medications significantly enhance subjective sleep perception and alleviate depressive symptoms. However, agomelatine may lack a definitive effect on improving objective sleep parameters in depressed patients. Future studies should involve larger, high-quality trials with unified methodologies to strengthen the reliability of conclusions."

Journal • Retrospective data • Review • Anesthesia • CNS Disorders • Depression • Insomnia • Mood Disorders • Pain • Psychiatry • Sleep Disorder

Evaluating the Effectiveness of Cyproheptadine on Acute Neuroleptic-induced Akathisia: A Double-blind Randomized Controlled Trial. (PubMed, J Clin Psychopharmacol) - "Cyproheptadine significantly reduces symptoms of antipsychotic-induced akathisia. Based on the evidence of this study, particularly the ARR and the NNT for achieving complete remission, it seems that cyproheptadine could be a potential alternative for managing akathisia induced by antipsychotic medications, especially in comparison to previous studies involving mirtazapine and propranolol."

Journal • CNS Disorders • Psychiatry

Progressive multifocal leukoencephalopathy associated with elranatamab therapy in relapsed/refractory multiple myeloma. (PubMed, J Oncol Pharm Pract) - "Despite treatment with intravenous immunoglobulin, mirtazapine, and compassionate-use nivolumab, her neurological status progressively worsened, necessitating intubation and intensive care management.DiscussionThis case suggests a probable association between elranatamab therapy and JC virus reactivation leading to PML. Early neuroimaging and cerebrospinal fluid JC virus testing, combined with proactive immunoglobulin replacement and systematic pharmacovigilance, are essential for timely diagnosis and improved outcomes. Overall, this case highlights the need for early JC virus monitoring and awareness of delayed neuroinfectious complications associated with BCMA-targeted immunotherapies."

Journal • CNS Disorders • Critical care • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Oncology • Rare Diseases

Body mass index but not percentage weight loss was associated with the race/ethnicity of patients with advanced lung cancer: a cross-sectional study. (PubMed, Ann Palliat Med) - "In patients with advanced lung cancer, BMI and total weight loss but not percentage change in weight was significantly associated with self-identified race/ethnicity at the time of Palliative Medicine consultation. On multivariate analysis, the percentage loss in weight was significantly influenced by the weight at first encounter but not race/ethnicity. Racial/ethnic variations in BMI but not percentage weight loss should be accounted for when diagnosing cancer cachexia and more research is needed."

IO biomarker • Journal • Observational data • Retrospective data • Cachexia • Lung Cancer • Oncology • Palliative care • Solid Tumor

A Neurotoxicity Mimic: Progressive Multifocal Leukoencephalopathy Following BCMA-Directed CART and Bispecific Therapies (TCT-ASTCT-CIBMTR 2026) - "He received cilta-cel as 5th line therapy following bridging with talquetamab...He was treated with high-dose IVIG, mirtazapine, and pembrolizumab... These cases highlight a devastating complication of BCMA-directed therapy. Increasing use of BCMA- targeted platforms warrants collaboration to define incidence, risk factors, and develop strategies for prevention and treatment. Progressive multifocal leukoencephalopathy is rare, but catastrophic complication of BCMA-directed immune therapies."

CNS Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Rare Diseases • CD4